These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 3567893)

  • 1. Generation of drug-resistant variants in metastatic B16 mouse melanoma cell lines.
    Cillo C; Dick JE; Ling V; Hill RP
    Cancer Res; 1987 May; 47(10):2604-8. PubMed ID: 3567893
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug resistance in KHT fibrosarcoma cell lines with different metastatic ability.
    Cillo C; Ling V; Hill RP
    Int J Cancer; 1989 Jan; 43(1):107-11. PubMed ID: 2910823
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High frequency of double drug resistance in the B16 melanoma cell line.
    McMillan TJ; Kalebic T; Stark GR; Hart IR
    Eur J Cancer; 1990; 26(5):565-7. PubMed ID: 2144741
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug sensitivity and metastatic ability in B16 melanoma cells.
    Jang A; Hill RP
    Clin Exp Metastasis; 1991; 9(4):393-402. PubMed ID: 1868629
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of N-(phosphonacetyl)-L-aspartate on murine tumors and normal tissues in vivo and in vitro and the relationship of sensitivity to rate of proliferation and level of aspartate transcarbamylase.
    Johnson RK; Swyryd EA; Stark GR
    Cancer Res; 1978 Feb; 38(2):371-8. PubMed ID: 620408
    [No Abstract]   [Full Text] [Related]  

  • 6. Biochemistry and clinical activity of N-(phosphonacetyl)-L-aspartate: a review.
    Grem JL; King SA; O'Dwyer PJ; Leyland-Jones B
    Cancer Res; 1988 Aug; 48(16):4441-54. PubMed ID: 3293772
    [No Abstract]   [Full Text] [Related]  

  • 7. Improved therapeutic index with sequential N-phosphonacetyl-L-aspartate plus high-dose methotrexate plus high-dose 5-fluorouracil and appropriate rescue.
    Martin DS; Stolfi RL; Sawyer RC; Spiegelman S; Young CW
    Cancer Res; 1983 Oct; 43(10):4653-61. PubMed ID: 6603903
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of tumor promoter 12-O-tetradecanoylphorbol-13-acetate on recovery of methotrexate-, N-(phosphonacetyl)-L-aspartate-, and cadmium-resistant colony-forming mouse and hamster cells.
    Bojan F; Kinsella AR; Fox M
    Cancer Res; 1983 Nov; 43(11):5217-21. PubMed ID: 6616458
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Collateral sensitivity to N-(phosphonacetyl)-L-aspartic acid in a line of P388 leukemia cells selected for resistance to L-(alpha S, 5S)-alpha-amino-3- chloro-4,5-dihydro-5-isoxazoleacetic acid (acivicin).
    Ardalan B; Jayaram HN; Johnson RK
    Cancer Res; 1983 Apr; 43(4):1598-601. PubMed ID: 6831405
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum uridine levels in patients receiving N-(phosphonacetyl)-L-aspartate.
    Karle JM; Anderson LW; Erlichman C; Cysyk RL
    Cancer Res; 1980 Aug; 40(8 Pt 1):2938-40. PubMed ID: 7388844
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phenotypic resistance to methotrexate and N-phosphonacetyl L-aspartate is induced by treatment with 12-O-tetradecanoylphorbol-13-acetate (TPA).
    Kinsella AR; Fox M
    Int J Cancer; 1988 Jul; 42(1):87-93. PubMed ID: 3391708
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of cell growth by N-(phosphonacetyl)-L-aspartate in human and murine cells in vitro.
    Leyva A; Appel H; Smith P; Lankelma J; Pinedo HM
    Cancer Lett; 1981 Mar; 12(1-2):169-73. PubMed ID: 7273001
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Decreasing sensitivity to cytotoxic agents parallels increasing tumorigenicity in human fibroblasts.
    Kinsella AR; Haran MS
    Cancer Res; 1991 Apr; 51(7):1855-9. PubMed ID: 2004369
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dynamic heterogeneity: rapid generation of metastatic variants in mouse B16 melanoma cells.
    Hill RP; Chambers AF; Ling V; Harris JF
    Science; 1984 Jun; 224(4652):998-1001. PubMed ID: 6719130
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Response of psoriasis to N-phosphonacetyl-L-aspartate.
    Earhart RH; DeConti RC; Rubin J; Ohnuma T
    Lancet; 1981 Jun; 1(8232):1257-8. PubMed ID: 6112581
    [No Abstract]   [Full Text] [Related]  

  • 16. Phase II evaluation of N-(phosphonacetyl-L-aspartic acid (PALA) in patients with advanced colorectal carcinoma.
    Carroll DS; Gralla RJ; Kemeny NE
    Cancer Treat Rep; 1980; 64(2-3):349-51. PubMed ID: 7407769
    [No Abstract]   [Full Text] [Related]  

  • 17. Expression of a Mr 41,000 glycoprotein associated with thrombin-independent platelet aggregation in high metastatic variants of murine B16 melanoma.
    Watanabe M; Sugimoto Y; Tsuruo T
    Cancer Res; 1990 Oct; 50(20):6657-62. PubMed ID: 2208129
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II evaluation of PALA and AMSA for patients with disseminated malignant melanoma.
    Creagan ET; Ahmann DL; Ingle JN; Purvis JD; Green SJ
    Cancer Treat Rep; 1981; 65(1-2):169. PubMed ID: 6894400
    [No Abstract]   [Full Text] [Related]  

  • 19. Increased methotrexate resistance and dhfr gene amplification as a consequence of induced Ha-ras expression in NIH 3T3 cells.
    Wani MA; Xu X; Stambrook PJ
    Cancer Res; 1994 May; 54(9):2504-8. PubMed ID: 8162600
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II evaluation of N-(phosphonacetyl)-L-aspartic acid (PALA) in patients with non-small cell carcinoma of the lung.
    Casper ES; Gralla RJ; Kelsen DP; Houghton A; Golbey RB; Young CW
    Cancer Treat Rep; 1980; 64(4-5):705-7. PubMed ID: 6448688
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.